ロード中...
Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
INTRODUCTION: Epigenetic modifications play an important role in progression and development of resistance in (V600E)BRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA m...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5687680/ https://ncbi.nlm.nih.gov/pubmed/29179510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21269 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|